Vol. 3 No. 1 (2023)
Reimbursement Reviews

Faricimab (Vabysmo)

decorative image

Published January 12, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses faricimab (Vabysmo) 6 mg (6 mg/0.05 mL solution) for intravitreal injection.
  • Indication: For the treatment of diabetic macular edema.